JB Pharma publishes sustainability report for FY 2022-23

JB Pharma publishes sustainability report for FY 2022-23

JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions

  • By IPP Bureau | September 12, 2023

J B Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharma companies in India, today published its 2nd Sustainability (ESG) Report. The report reflects JB Pharma’s priorities in building sustainable, equitable and resilient systems to promulgate good health for the current and future generations.

While the overall Green House Gases (GHG) intensity (i.e. Scope 1 & Scope 2) has been reduced by 19% as compared to last year. This financial year also witnessed the completion of calculating scope 3 emissions for the first time for JB Pharma, where focus will be on total emissions across the organization and the external supply chain. The initiation of a renewable hybrid power supply (wind & solar) across all manufacturing facilities in India resulted in 8464.89 GJ energy being derived from these sources.

Nikhil Chopra, CEO & Whole Time Director, JB Pharma at the launch of the report said, “ESG is an imperative for progressive businesses operating in a dynamic environment. The 2nd report highlights progress made and an action-oriented approach for the next financial year. It is prepared following the international reporting frameworks i.e. Global Reporting Initiative (GRI) as its core standard, and linkages with the United Nations Sustainable Development Goals (UN SDGs).”

“People, patients and planet will always remain at the fulcrum of JB’s existence as we constantly evolve and embed responsible practices for a sustainable world. Underpinned by a growth- mindset, robust governance systems and state-of-the-art facilities, JB Pharma is committed towards providing quality and cost-effective medicines across the globe.” He added.

Nearly 40,000 litres of water was treated through Effluent Treatment Plants (ETP) and re-used with all manufacturing sites being zero liquid discharge. 93.6% of non-hazardous waste generated was diverted from disposal and there was 32.4% decrease in hazardous waste sent to landfills. Materiality assessment were revisited basis which key policies were developed which serve as a driving force for implementing best governance practices across the entire value chain.

As employees are the fulcrum of the organisation bringing goals to fruition, enhancing their holistic well- being is of paramount importance in JB Pharma. In line with organizational ethos, initiatives like JB Cares – a 360-degree in-house wellness app was introduced with the aim of amplifying employee physical and mental well-being. A continuous learning and development framework (I.D.E.A) with innovative leadership development, talent development and upskilling programmes at various levels of the workforce is underway to stimulate employees’ personal as well as organisational goals.

The organisation witnessed a 14.4% increase in women representation since 2019-20, with 14% increase in women representation across fields, historically dominated by their counterparts in the industry. Championing a culture of inclusion and belonging, JB Pharma has initiated drafting of a charter and framework for Diversity, Equity and Inclusion (DE&I) framework which helps in nurturing talent and creating equal opportunities in the organization.


Upcoming E-conference

Other Related stories